Identification of monoclonal antibody variants involved in aggregate formation - Part 2: Hydrophobicity variants

Eur J Pharm Biopharm. 2021 Mar:160:134-142. doi: 10.1016/j.ejpb.2021.01.006. Epub 2021 Jan 30.

Abstract

Monoclonal antibodies (mAbs) are valuable tools both in therapy and in diagnostic. Their tendency to aggregate is a serious concern. Since a mAb drug substance (DS) is composed of different variants, it is important for manufacturers to know the behavior and stability not only of the mAb as a whole, but also of the variants contained in the product. We present a method to separate hydrophobicity variants of a mAb and subsequently analyzed these variants for stability and aggregation propensity. We identified a potentially aggregation prone hydrophilic variant which is interrelated with another previously identified aggregation prone acidic charge variant. Additionally, we assessed the risk posed by the aggregation prone variant to the DS by spiking hydrophobicity variants into DS and did not observe an enhanced aggregation propensity. Thus we present an approach to separate, characterize and analyze the criticality of aggregation prone variants in protein DS which is a step forward to further assure drug safety.

Keywords: Protein aggregation; Protein stability; Semi-preparative HIC; mAb hydrophobicity variants.

MeSH terms

  • Antibodies, Monoclonal / chemistry*
  • Biological Products / chemistry*
  • Drug Stability
  • Drug Storage
  • Hydrophobic and Hydrophilic Interactions
  • Protein Aggregates*

Substances

  • Antibodies, Monoclonal
  • Biological Products
  • Protein Aggregates